Hematology

Latest News
April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 21st 2025

Cardiovascular Risk Factors Impact Outcomes in MPNs

April 18th 2025

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 16th 2025

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo
Video Interviews
View All
April 27th 2025

Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD

April 21st 2025

Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD

April 18th 2025

Navigating Value, Efficacy in Modern CLL Treatment: Pierluigi Porcu, MD

April 10th 2025

Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

April 1st 2025

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

March 19th 2025

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

March 17th 2025

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

March 7th 2025

Overcoming Delays in CAR T for Large B-Cell Lymphoma

March 5th 2025

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Podcasts
View All
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

May 5th 2018

Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 14th 2017

Five Years of Reducing Overuse of Medical Services With Choosing Wisely

More News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
April 10th 2025

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
April 8th 2025

Immune Microenvironment a Key Target in CLL

Jared Kaltwasser
A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw
In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.
FDA approval-Olivier Le Moal-stock.adobe.com
March 28th 2025

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

Giuliana Grossi
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi).
ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

Rose McNulty
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
ASH logo | images: ASH
March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

Mary Caffrey
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
CAR T | Image Credit: © Funny-stock.adobe.com
March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Maggie L. Shaw
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com
March 20th 2025

In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

Hayden E. Klein
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.
Orca-T is manufactured with highly purified regulatory T cells, hematopoietic stem cells, and conventional T cells from peripheral blood from matched donors. | Image credit: fotogurmespb - stock.adobe.com.jpg
March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

Rose McNulty
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.
CLL | Image credit: jarun011 – stock.adobe.com
March 19th 2025

Newer CLL Therapies Show Superior Long-Term Disease Control

Hayden E. Klein
Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.
Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com
March 11th 2025

Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL

Jared Kaltwasser
Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.
Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com
March 5th 2025

Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better

Hayden E. Klein
Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com
February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Sabarish Ayyappan, MD
February 27th 2025

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Kyle Munz Sabarish Ayyappan, MD
More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.
Sabarish Ayyappan, MD
February 24th 2025

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Kyle Munz Sabarish Ayyappan, MD
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
Frederick L. Locke, MD
February 24th 2025

Allogeneic vs Autologous CAR T-Cell Therapy Explained

Maggie L. Shaw Frederick L. Locke, MD
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.
Sabarish Ayyappan, MD
February 20th 2025

Geographic Barriers Impede Access to Novel Cancer Treatments

Kyle Munz Sabarish Ayyappan, MD
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com
February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

Kyle Munz
A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.
Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Maggie L. Shaw
Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).
Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com
February 10th 2025

Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers

Hayden E. Klein
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.
Mikkael Sekeres, MD
February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

Rose McNulty Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg
February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Maggie L. Shaw
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.
cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com
February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz
The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.
Mikkael Sekeres, MD
February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

Mikkael A. Sekeres, MD Rose McNulty
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).
12345678
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo